View Author
patient myeloma bortezomib therapy study dexamethasone response trial blood treatment thalidomide cancer university serum survival disease phase signi lenalidomide factor hospital group myeloma patients analysis result neuropathy transplantation high-dose department table progression richardson journal combination signi ficantly month leukemia cell transplantation number marrow hematology grade regimen randomized level incidence chain marker protein high-dose dexamethasone center light outcome chemotherapy ef ficacy j clin oncol british journal agent autologou response rate prognostic cycle score institute cyclophosphamide research mobilization fication impact induction baseline risk factors guideline reduction medicine novel collection plasma subgroups cell collection
10 Most Recent Publications
|
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
(Article)
Fernández De Larrea, C. Kyle, R. Kumar, S. Mahindra, A. Comenzo, R.L. Palumbo, A. Mazumber, A. Anderson, K.C. Richardson, P.G. Badros, A.Z. Caers, J. Cavo, M. Durie, B.G.M. Leleu, X. Dimopoulos, M.A. Chim, C.S. Schots, R. Noeul, A. Fantl, D. Mellqvist, U.H. Landgren, O. Chanan-Khan, A. Moreau, P. Ludwig, H. Fonseca, R. Merlini, G. Lahuerta, J.J. Bladé, J. Orlowski, R.Z. Shah, J.J. Usmani, S.M. Vesole, D. Hajek, R. San Miguel, J-F. Sezer, O. Sonneveld, P. |
2013-04-01
|
|
International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
(Article)
Cavo, M. Rajkumar, S.V. Sonneveld, P. Boccadoro, M. Anderson, K.C. Richardson, P.G. Bensinger, W. Johnsen, H.E. Kroeger, N. Gahrton, G. Bergsagel, P.L. Vesole, D.H. Palumbo, A. Einsele, H. Jagannath, S. Niesvizky, R. Durie, B.G.M. Miguel, J.S. Lonial, S. Moreau, P. Orlowski, R.Z. Bladé, J. Sezer, O. Ludwig, H. Dimopoulos, M.A. Attal, M. |
2011-06-09
|
|
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
(Article)
Munshi, N.C. Anderson, K.C. Jagannath, S. Hajek, R. Sezer, O. Kyle, R. Sonneveld, P. Cavo, M. Rajkumar, S.V. San-Miguel, J-F. Crowley, J. Avet-Loiseau, H. Bergsagel, P.L. Shaughnessy, J. Palumbo, A. Durie, B.G.M. Fonseca, R. Stewart, A.K. Harousseau, J-L. Dimopoulos, M.A. |
2011-05-05
|
|
The use of biochemical markers of bone remodeling in multiple myeloma: A report of the International Myeloma Working Group
(Article)
Terpos, E. Dimopoulos, M.A. Palumbo, A. Sonneveld, P. Drake, M.T. Harousseau, J-L. Anderson, K.C. Durie, B.G.M. Sezer, O. Roodman, D. Abildgaard, N. Vescio, R. Tosi, P. Garcia-Sanz, R. Davies, F. Chanan-Khan, A. |
2010-10-01
|
|
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
(Article)
Kyle, R. Durie, B.G.M. San Miguel, J-F. Avet-Loiseau, H. Hajek, R. Chen, W. Anderson, K.C. Ludwig, H. Sonneveld, P. Pavlovsky, S. Palumbo, A. Richardson, P.G. Rajkumar, S.V. Barlogie, B. Greipp, P. Vescio, R. Turesson, I. Westin, J. Boccadoro, M. Landgren, O. Bladé, J. Merlini, G. Kröger, N. Einsele, H. Vesole, D. Dimopoulos, M.A. |
2010-04-22
|
|
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
(Article)
Kumar, S. Giralt, S. Miguel, J.S. Ludwig, H. Bergsagel, L. Bladé, J. Lonial, S. Anderson, K.C. Tosi, P. Sonneveld, P. Sezer, O. Vesole, D. Stadtmauer, E.A. Cavo, M. Einsele, H. Richardson, P.G. Durie, B.G.M. Rajkumar, S.V. Harousseau, J-L. Palumbo, A. Bensinger, W. Comenzo, R.L. Lentzsch, S. Munshi, N.C. Niesvizky, R. |
2009-11-20
|
|
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
(Article)
Vogl, D.T. Stadtmauer, E.A. Anderson, K.C. Richardson, P.G. Sonneveld, P. Schuster, M.W. Irwin, D. Facon, T. Harousseau, J-L. Boral, A.L. Neuwirth, R. |
2009-11-01
|
|
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
(Article)
Giralt, S. Stadtmauer, E.A. Merlini, G. San Miguel, J. Ludwig, H. Hajek, R. Jagannath, S. Blade, J. Lonial, S. Dimopoulos, M.A. Einsele, H. Barlogie, B. Harousseau, J-L. Anderson, K.C. Gertz, M. Attal, M. Tosi, P. Sonneveld, P. Boccadoro, M. Morgan, G. Sezer, O. Mateos, M.V. Cavo, M. Palumbo, A. Joshua, D. Turesson, I. Chen, W. Shimizu, K. Powles, R. Richardson, P.G. Niesvizky, R. Rajkumar, S.V. Durie, B.G.M. Bensinger, W. Comenzo, R.L. Kumar, S. Munshi, N.C. Dispenzieri, A. Kyle, R. |
2009-06-26
|
|
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
(Article)
Palumbo, A. Sezer, O. Kumar, S. Hajek, R. Giralt, S. Bringhen, S. Anderson, K.C. Richardson, P.G. Cavo, M. Davies, F. Bladé, J. Einsele, H. Kyle, R. Dimopoulos, M.A. Spencer, A. Dispenzieri, A. Reiman, T. Shimizu, K. Lee, J.H. Attal, M. Boccadoro, M. Mateos, M.V. Chen, W. Miguel, J.S. Ludwig, H. Joshua, D. Chim, J. Hungria, V. Turesson, I. Durie, B.G.M. Lonial, S. Orlowski, R.Z. Moreau, P. Niesvizky, R. Morgan, G. Comenzo, R.L. Sonneveld, P. |
2009-06-08
|
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
(Article)
Richardson, P.G. Sonneveld, P. Bladé, J. Boccadoro, M. Cavenagh, J. Boral, A.L. Esseltine, D-L. Wen, P.Y. Amato, A.A. Anderson, K.C. San Miguel, J-F. Schuster, M.W. Stadtmauer, E.A. Facon, T. Harousseau, J-L. Ben-Yehuda, D. Lonial, S. Goldschmidt, H. Reece, D. |
2009-03-01
|
